Inventor · disambiguated record
Eric Konofal
Also filed as: KONOFAL ERIC
4 granted patents·16 pending applications·15 citations·filing 2004–2023
70Inventor score
Files withNLS PHARMACEUTICS AG8KONOFAL ERIC4ASSIST PUBL HOPITAUX DE PARIS2NLS 1 PHARMA AG2ASSIST PUBLIQUE - HOPITAUX DE PARIS1
Top patents by PatentIndex Score
20 records- 0185US8293779B2Mazindol combination in the treatment of attention deficit/hyperactivityKONOFAL ERIC·Filed 2007·Granted Oct 23, 2012·11 cites·15 claims
- 0276US2024108605A1Mazindol combination in the treatment of attention-deficit/hyperactivityNLS PHARMACEUTICS AG·Filed 2023·Application pending·0 cites
- 0374US9637447B2Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereofKONOFAL ERIC·Filed 2012·Granted May 2, 2017·4 cites·11 claims
- 0466US2022054471A1Phacetoperane for treating of attention deficit hyperactivity disorderNLS PHARMACEUTICS AG·Filed 2021·Application pending·0 cites
- 0563US2021093614A1Mazindol combination in the treatment of attention-deficit/hyperactivityNLS PHARMACEUTICS AG·Filed 2020·Application pending·0 cites
- 0659US2019328714A1Mazindol combination in the treatment of attention-deficit/hyperactivityNLS 1 PHARMA AG·Filed 2019·Application pending·0 cites
- 0757US2017252325A1Mazindol combination in the treatment of attention deficit/hyperactivityNL S-1 PHARMA AG·Filed 2017·Application pending·0 cites
- 0856US2012308668A1Mazindol combination in the treatment of attention deficit/hyperactivityKONOFAL ERIC·Filed 2012·Application pending·0 cites
- 0955US2016030394A1Mazindol Combination In The Treatment Of Attention-Deficit/HyperactivityASSIST PUBL HOPITAUX DE PARIS·Filed 2015·Application pending·0 cites
- 1054US2011183009A1Mazindol Combination In The Treatment Of Attention-Deficit/HyperactivityASSIST PUBL HOPITAUX DE PARIS·Filed 2011·Application pending·0 cites
- 1153US10456387B2Phacetoperane for treating of attention deficit hyperactivity disorderNLS PHARMA AG·Filed 2018·Granted Oct 29, 2019·0 cites·9 claims
- 1252US2017216258A1Mazindol combination in the treatment of attention-deficit/hyperactivityNLS-1 PHARMA AG·Filed 2017·Application pending·0 cites
- 1351US2020061044A1Phacetoperane for treating of attention deficit hyperactivity disorderNLS PHARMACEUTICS AG·Filed 2019·Application pending·0 cites
- 1451US2015038533A1Phacetoperane for the treatment of attention-deficit hyperactivity disorderASSISTANCE PUBLIQUE HOPTIAUX DE PARIS·Filed 2012·Application pending·0 cites
- 1547US2025268859A1Oxafuramine, (1r)-n-ethyl-1-[(2r)-oxolan-2-yl]-2-phenylethanamine, hydrochloride and derivatives thereof for treating alzheimer's disease (ad), vascular dementia, dementia with lewy bodies (dlb), mixed dementia, frontotemporal lobar degeneration (ftld), and parkinson's disease (pd)NLS PHARMACEUTICS AG·Filed 2022·Application pending·0 cites
- 1647US2025049737A1Lauflumide and derivatives thereof for treating chronic fatigue syndrome and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)NLS PHARMACEUTICS AG·Filed 2022·Application pending·0 cites
- 1747US2024316023A1Benedin, piperidine, 2-benzhydryl-3-hydroxy-n-methyl-, hydrochloride and derivatives thereof for use in treating kleine-levin syndromeNLS PHARMACEUTICS AG·Filed 2022·Application pending·0 cites
- 1847US2025082598A1Melafenoxate, 2-(1-adamantylamino)ethyl 2-(4-chlorophenoxy)acetate and derivatives thereof for treating circadian rhythm sleep disorders with neurodegenerative diseases such as Alzheimer's diseaseNLS PHARMACEUTICS AG·Filed 2022·Application pending·0 cites
- 1941US10532100B2Use of iron for treating attention deficit hyperactivity disorder in childrenKONOFAL ERIC·Filed 2004·Granted Jan 14, 2020·0 cites·9 claims
- 2041US2017151197A1Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereofASSIST PUBLIQUE - HOPITAUX DE PARIS·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Eric Konofal files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →